FDA approves BeOne's Tevimbra combo for HER2+ stomach cancer
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235) announced that the U.S. Food and Drug Administration has approved a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
